The new circular with which the Ministry of Health has updated the recommendations on the Vaxzevria vaccine by AstraZeneca is ready.
The circular - sent to Regions, institutions and associations - reiterates that the vaccine is approved from 18 years of age.
"On the basis of current evidence, taking into account the low risk of adverse reactions of the thromboembolic type in the face of the high mortality from COVID-19 in the most advanced age groups - we read - it is reported that its preferential use is recommended in people above 60 years ".
"Those who have already received a first dose of Vaxzevria can complete the course with the same vaccine."
The Technical Scientific Commission (CTS) of the Italian Medicines Agency (Aifa) notes that "at the moment no similar risk signals" of thrombotic events "have been identified for mRNA vaccines. It is not yet possible to express an opinion on the matter. to other vaccines that use viral vaccination platforms ".
This is what is stated in the CTS opinion attached to the circular of the Ministry of Health on the updating of the recommendations for the AstraZeneca anti-Covid vaccine.
The CTS underlines that the benefit / risk balance of the vaccine is confirmed "overall positive".
